Dr. Reddys Laboratories updated the exchanges on the conclusion of USFDA's inspection at two of its facilities.
The company in a filing stated, "This is in reference to the audit of our Formulations Manufacturing Plants ('Vizag SEZ Plant 1 - FTO 7' and 'Vizag SEZ Plant 2 - FTO 9') at Duvvada, Visakhapatnam, which was completed on June 21, 2019 and our intimation dated June 22, 2019. We have now received an EIR from the US FDA, indicating closure of this audit."
The USFDA issues EIR on closure of inspection of an establishment that is the subject of an USFDA or USFDA-contracted inspection.
Dr Reddys Laboratories Ltd is currently trading at Rs2,743.50 down by Rs21.8 or 0.79% from its previous closing of Rs2,765.30 on the BSE.
The scrip opened at Rs2,788 and has touched a high and low of Rs2,791 and Rs2,737.50 respectively. So far 2,81,991 (NSE+BSE) shares were traded on the counter. The current market cap of the company is Rs45,944.28cr.
Post a Comment